Life Science & Biotech

Lilly drug shows promise as lung cancer treatment

February 19, 2014
J.K. Wall
Shares of Eli Lilly and Co. rose as much as 3.8 percent Wednesday morning after the Indianapolis-based drugmaker revealed that an experimental drug boosted overall survival among lung cancer patients in a large trial.
More

Ex-Marcadia execs raise $1.7M to launch drug firmRestricted Content

February 15, 2014
J.K. Wall
Fritz French and Richard DiMarchi, the former leaders of Marcadia Biotech, have teamed up to launch the diabetes drug development firm Calibrium LLC.
More

Deals up, dollars down in 2013 for Indiana life sciences firms

February 10, 2014
J.K. Wall
Venture capitalists and angel investors put a combined $31.9 million into 18 life sciences companies last year, with some of the largest amounts going to Nextremity Solutions, hc1.com and FAST BioMedical.
More

Biomet reaches $50M settlement in hip-replacement case

February 7, 2014
Associated Press
Indiana-based Biomet Inc. has agreed to pay a base rate of $200,000 each to hundreds of people who received artificial hips that were later replaced.
More

Purdue, Cook create $12M fund for life-science startups

February 4, 2014
 IBJ Staff
The Foundry Investment Fund will join with other investors to provide funding for companies that use Purdue-licensed technology or expertise in human and animal health and plant sciences.
More

Rival's lawsuit could delay launch of new Lilly insulin

January 31, 2014
J.K. Wall
Paris-based Sanofi sued Eli Lilly and Co. on Thursday for patent infringement. That suit triggers an automatic 30-month delay on Lilly’s plans to launch a similar version of Sanofi's once-a-day insulin Lantus.
More

Lilly said to be willing to pay $3.7B for biotech firm

January 27, 2014
J.K. Wall
A newspaper says Eli Lilly and Co. is a leading contender to acquire a Massachusetts-based biotech company with a troubled leukemia drug.
More

IU professors' invention tracks eyes to detect brain injuries

January 11, 2014
Anthony Schoettle
Two Indiana University School of Optometry professors are tackling diagnosis of one of the most difficult medical problems facing sports teams at every level: head injuries.
More

Funding drought pinches life sciences firms

January 11, 2014
J.K. Wall
Nationally, venture capital investments into life sciences firms totaled $4.9 billion during the first nine months of 2013, down 30 percent from the same period in 2008, according to data from Thomson Reuters and PricewaterhouseCoopers. In Indiana, life sciences firms raised $21 million during the first nine months of the year, far lower than any year since 2003.
More

State lags city with science, tech jobs

January 4, 2014
Dan Human
Careers in science, technology, engineering and math—typically referred to as STEM fields—have surged in growth compared to other careers in Marion and Hamilton counties. But the rest of Indiana has barely budged from the early 2000s.
More

Lilly set to fall off second patent cliff

December 9, 2013
J.K. Wall
Eli Lilly and Co. on Wednesday will fall off its second “patent cliff” in as many years as its best-selling drug Cymbalta sees its U.S. patents expire.
More

J&J to pay $2.5B to settle hip replacement suits

November 19, 2013
Associated Press
The agreement is one of the largest ever for the medical device industry. It resolves an estimated 8,000 cases of patients who had to have the company's metal ball-and-socket hip implant removed or replaced. The implants were made by J&J's Indiana-based DePuy unit.
More

MCCANN: Energy research evolving to meet massive demandsRestricted Content

November 16, 2013
Maureen McCann / Special to IBJ
The days of lone-wolf researchers shouting 'Eureka' are over.
More

Purdue makes big push into state's pharma industry

November 2, 2013
J.K. Wall
With a $60 million-plus investment, the university aims to take molecules from discovery to clinical trials.
More

Sale may extricate Harlan Labs from its debt problems

November 2, 2013
Greg Andrews
San Francisco-based Genstar Capital is exploring selling the 2,600-employee company in the wake of failing early this year to renegotiate the company’s massive debt load.
More

DowAgrosciences cultivates sales record, but profit withers

October 24, 2013
 IBJ Staff and Associated Press
Despite a boost in third-quarter revenue due to crop-protection products, profit for the local unit of Dow Chemical tumbled more than 71 percent.
More

State medical institute snares $30M grant from feds

October 23, 2013
 IBJ Staff
A consortium of Indiana University, Purdue University and University of Notre Dame can operate for another five years with the grant funds.
More

Analysts: Investors wrong to dump Endocyte

October 14, 2013
J.K. Wall
Investors on Friday dumped shares of West Lafayette-based Endocyte Inc. after an independent analysis said an experimental lung cancer drug is unlikely to be declared superior to existing chemotherapy. But two analysts say, to the contrary, the analysis shows the prospects for Endocyte’s drug are as good as ever.
More

Lilly scientists stole $55 million in trade secrets, indictment alleges

October 8, 2013
J.K. Wall
Three former employees of Eli Lilly and Co. allegedly transferred trade secrets that Lilly values at more than $55 million to a competing Chinese drug company, according to an indictment unsealed Tuesday in federal court.
More

Dow Agro wins latest patent case involving Enlist product

October 8, 2013
 IBJ Staff
The suit, filed in January 2012 by South African-based Bayer CropScience SA, charged that Dow Agro’s Enlist E3 soybean seed infringed one of its patents.
More

Technology on track to dramatically change health care

October 5, 2013
J.K. Wall
Cost pressures are forcing health care providers to extend the reach of limited resources.
More

Pence pleads for end to medical device tax

October 1, 2013
 The Statehouse File
Republican Gov. Mike Pence wrote a letter Monday urging members of the U.S. Senate to vote to repeal the medical device tax that is helping to finance Obamacare. But the Senate on Monday night voted not to repeal the tax, with all 54 Democrats voting to keep it.
More

Auction lands $2.1 million for Elona Biotech assets

September 27, 2013
 IBJ Staff
Elona went into receivership in June after Greenwood officials filed a foreclosure lawsuit against the firm. The company failed after receiving more than $8 million in economic development incentives from the city over the past three years.
More

Device prices plunge as hospitals pay less to fix hearts, hips

September 23, 2013
Bloomberg News
Prices paid in the United States for medical devices, including those made by Indiana-based manufacturers, have plunged as much as one-third since 2007 as hospitals clamped down on spending.
More

After years of success, Harlan Laboratories caught in debt viseRestricted Content

September 7, 2013
Greg Andrews
The company may violate loan covenants in the next three to six months, and its ability to refinance a $280 million loan that matures in July 2014 is “highly questionable,” Moody’s says.
More
Page  << 1 2 3 4 5 6 7 8 9 10 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. With Pence running the ship good luck with a new government building on the site. He does everything on the cheap except unnecessary roads line a new beltway( like we need that). Things like state of the art office buildings and light rail will never be seen as an asset to these types. They don't get that these are the things that help a city prosper.

  2. Does the $100,000,000,000 include salaries for members of Congress?

  3. "But that doesn't change how the piece plays to most of the people who will see it." If it stands out so little during the day as you seem to suggest maybe most of the people who actually see it will be those present when it is dark enough to experience its full effects.

  4. That's the mentality of most retail marketers. In this case Leo was asked to build the brand. HHG then had a bad sales quarter and rather than stay the course, now want to go back to the schlock that Zimmerman provides (at a considerable cut in price.) And while HHG salesmen are, by far, the pushiest salesmen I have ever experienced, I believe they are NOT paid on commission. But that doesn't mean they aren't trained to be aggressive.

  5. The reason HHG's sales team hits you from the moment you walk through the door is the same reason car salesmen do the same thing: Commission. HHG's folks are paid by commission they and need to hit sales targets or get cut, while BB does not. The sales figures are aggressive, so turnover rate is high. Electronics are the largest commission earners along with non-needed warranties, service plans etc, known in the industry as 'cheese'. The wholesale base price is listed on the cryptic price tag in the string of numbers near the bar code. Know how to decipher it and you get things at cost, with little to no commission to the sales persons. Whether or not this is fair, is more of a moral question than a financial one.

ADVERTISEMENT